Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, with a rise of nearly 13% in the afternoon and a cumulative increase of over 130% in the past two weeks, reflecting strong market interest and strategic developments [1] Group 1: Strategic Developments - Huajian Medical has entered into a strategic cooperation framework agreement with BGI CoWin to establish the IVD-BGI CoWin Innovation Drug Intellectual Property Tokenization Fund, which will invest in projects under a NewCo + RWA Web3 exchange ecosystem model [1] - BGI CoWin, initiated by the biotechnology leader BGI Genomics, brings years of investment experience and project resources in the fields of innovative medicine and drugs [1] Group 2: Market Performance - The company's market capitalization has surged from HKD 3.6 billion to nearly HKD 8 billion following a series of strategic actions, including the announcement of a dual primary listing in the U.S. and the launch of a new brand logo [1] - The combination of "stablecoins + medical RWA" has positioned Huajian Medical as a "new species" in the capital market, indicating a transformative approach to traditional medical finance [1] Group 3: Future Prospects - Applications for stablecoin licenses in New York and Hong Kong are ongoing, and the listing on NASDAQ has yet to occur, suggesting potential future growth and expansion opportunities for the company [1] - The strategic maneuvers in July are likened to a surgical operation, aiming to leverage Web3 technology to convert innovative medical drug assets into "digital gold" on the blockchain [1]

Group 1 - Huajian Medical (01931) saw its stock price increase by nearly 13%, with a cumulative rise of over 130% in the past two weeks, reaching 5.12 HKD per share and a trading volume of 9.56 million HKD [1] - The company announced a strategic cooperation framework agreement with BGI CoWin to establish an innovative drug intellectual property tokenization fund, which will invest in projects under the NewCo+RWA Web3 exchange ecosystem in Hong Kong, the US, or other overseas regions [1] - BGI CoWin, initiated by the biotechnology leader BGI Genomics (300676), has extensive domestic and international investment experience and project resources in the fields of innovative medicine and drugs [1] Group 2 - Huajian Medical's market capitalization surged from 3.6 billion HKD to nearly 8 billion HKD due to seven strategic actions taken in July, including a dual primary listing announcement in the US and the launch of a new brand logo [2] - The company is positioning itself as a "new species" in the capital market through a cross-industry combination of "stablecoins + medical RWA" [2] - Ongoing applications for stablecoin licenses in New York and Hong Kong, along with the upcoming Nasdaq listing, signify the company's strategic thrust into transforming traditional medical finance by turning innovative drug assets into on-chain "digital gold" [2]

Core Viewpoint - Huajian Medical has transformed from an IVD distributor to a "medical innovation drug chain investment bank" within 18 days, driven by a series of strategic actions and market enthusiasm, resulting in a significant increase in market capitalization from 3.6 billion to nearly 8 billion HKD [1][7]. Group 1: Strategic Actions - On July 14, Huajian Medical announced its plan for a dual primary listing on NASDAQ to expand its international shareholder base [4]. - Three days later, the company introduced the world's first medical innovation drug RWA exchange, IVDNewCo Exchange, along with a supporting stablecoin, IVDDollar (IVDD) [4]. - The establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York was completed on July 20, with applications for stablecoin licenses submitted to the SEC and CFTC [4]. - From July 23 to 28, the company executed three high-priced buybacks, spending over 6.13 million HKD to repurchase 1.721 million shares, with average transaction prices rising from 3.16 HKD to 3.67 HKD [4]. - On July 29, the subsidiary Weida secured a multi-million HKD revolving loan led by East Asia Bank, showcasing financial institutions' endorsement of the company's development [4]. - A brand strategy upgrade was announced on July 30, with a new logo and a redefined brand essence of "Innovation-Verification-Development" [4]. - The same day, a partnership was formed with BGI's CoWin to establish an innovative drug intellectual property tokenization fund, facilitating the last mile of medical asset blockchain integration [4]. Group 2: Market Dynamics - The innovative drug industry is experiencing a value reassessment, with 48 out of 93 new drugs approved by the drug regulatory agency in 2024 being innovative drugs, and the scale of outbound licensing transactions soaring to 51.9 billion USD [8]. - As of July 29, the China Securities Hong Kong Stock Connect Innovative Drug Index has risen over 124% from its low point at the beginning of the year, with 16 innovative drug funds doubling their returns [8]. - The global regulatory landscape for stablecoins is evolving, with the U.S. "Genius Act" and Hong Kong's stablecoin regulations coming into effect, establishing a compliance network across Europe, the U.S., and Asia [8]. Group 3: Valuation Revolution - Following the announcement of the dual listing on July 14, Huajian Medical's stock price began a rapid ascent, with a cumulative increase of 75.1% from July 14 to 21 [9]. - On July 31, the stock price peaked at 4.99 HKD, marking a 15.78% increase for the day, and pushing the market capitalization to 8 billion HKD [9]. - The company's valuation is shifting from a traditional IVD distributor's sales multiple to an ecological premium associated with the medical RWA exchange [9]. Group 4: Future Outlook - Huajian Medical aims to become a leader in the medical RWA sector, akin to NASDAQ for medical asset tokenization, Visa for stablecoin payment scenarios, and Apple for integrating technology, assets, and capital into a closed loop [12]. - The global RWA market is projected to reach 16.1 trillion USD by 2030, with stablecoin transaction volumes expected to surpass Visa in 2024 [10]. - The company's strategy involves creating a closed-loop ecosystem that captures innovative drug pipelines, facilitates RWA tokenization, and enables payment settlements through IVDD stablecoin [10].

Core Viewpoint - The rapid transformation of Huajian Medical into a "new species" in the capital market is driven by its strategic actions, including a dual primary listing in the U.S. and the launch of innovative financial products, resulting in a significant increase in market capitalization from 3.6 billion to nearly 8 billion HKD within a month [1][4][9]. Group 1: Strategic Actions - On July 14, Huajian Medical announced its plan for a dual primary listing on NASDAQ to expand its international shareholder base [4]. - Three days later, the company introduced the world's first medical innovation drug RWA exchange, IVDNewCo Exchange, along with a stablecoin, IVDDollar [5]. - The establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York was announced on July 20, alongside applications for stablecoin licenses to the SEC and CFTC [5]. - From July 23 to 28, the company executed three high-priced share buybacks, spending over 6.13 million HKD to repurchase 1.721 million shares, with average transaction prices rising from 3.16 HKD to 3.67 HKD [5]. - On July 29, the subsidiary Weishida secured a multi-hundred million HKD revolving loan led by East Asia Bank, indicating strong backing from financial institutions [5]. - A brand strategy upgrade was announced on July 30, featuring a new logo symbolizing "innovation-validation-development" [5]. - The same day, a partnership with BGI Group was established to create an innovative drug intellectual property tokenization fund, enhancing the integration of medical assets on the blockchain [5]. Group 2: Market Dynamics - The innovative drug industry is experiencing a value reassessment, with 48 out of 93 new drugs approved by the drug regulatory agency in 2024 being innovative drugs, and the scale of outbound licensing transactions soaring to 51.9 billion USD [10]. - As of July 29, the China Securities Hong Kong Stock Connect Innovative Drug Index has risen over 124% from its low point at the beginning of the year, with 16 innovative drug funds doubling their returns [10]. - The global regulatory landscape for stablecoins is evolving, with the U.S. "Genius Act" and Hong Kong's stablecoin regulations coming into effect, establishing a compliance network across Europe, the U.S., and Asia [10]. Group 3: Valuation Revolution - Following the dual listing announcement on July 14, Huajian Medical's stock price surged, with a cumulative increase of 75.1% from July 14 to 21, and a peak price of 4.99 HKD per share on July 31, pushing its market capitalization to 8 billion HKD [11]. - The company's valuation is shifting from traditional IVD distribution metrics to a premium associated with its new role as a medical RWA exchange [11]. Group 4: Future Outlook - The global RWA market is projected to reach 16.1 trillion USD by 2030, with stablecoin transaction volumes expected to surpass Visa's by 2024 [12]. - Huajian Medical aims to create a closed-loop ecosystem, capturing innovative drug pipelines, tokenizing RWA, and facilitating payments through its stablecoin [12]. - The company aspires to become a leader in the medical RWA sector, akin to NASDAQ for asset tokenization, Visa for stablecoin payments, and Apple for integrating technology and capital [14].

Core Insights - Huajian Medical (01931) has signed a strategic cooperation framework agreement with BGI CoWin to establish the "Huajian-BGI CoWin Innovative Drug Intellectual Property Tokenization Fund" aimed at investing in Web3 exchange ecosystem projects in Hong Kong and the US [1][6][7] - Following the announcement, Huajian Medical's stock price surged by 15.78%, nearing HKD 5 per share, with a market capitalization reaching HKD 8 billion [3][6] - The fund will address long-standing industry challenges by tokenizing high-value medical assets, allowing ordinary investors access to clinical-stage drug development [6][10] Group 1: Fund Structure and Strategy - The framework agreement outlines that Huajian Medical or its designated entity will act as a limited partner, while BGI CoWin will serve as the general partner responsible for fund management [7] - The fund aims to leverage BGI CoWin's resources in innovative medical projects to select high-quality targets for investment [7][9] - The establishment of the fund coincides with a significant recovery in the innovative drug capital market, with 18 companies in the healthcare sector successfully listing and raising over 18 billion yuan in the first half of the year [7][10] Group 2: Web3 Ecosystem Development - The fund represents a key component of Huajian Medical's "NewCo + RWA + Stablecoin" strategy, which aims to reshape the global value chain of innovative drug assets [8][9] - BGI CoWin will provide comprehensive services from due diligence to transaction design for selected pharmaceutical companies or target assets [9] - Huajian Medical has registered a wholly-owned subsidiary in New York and is applying for stablecoin licenses, positioning itself advantageously in the regulatory landscape [9][10] Group 3: Market Potential and Innovation - The global RWA market is projected to reach USD 16.1 trillion by 2030, representing 10% of global GDP, with innovative drug asset tokenization having inherent advantages [10][11] - The traditional pharmaceutical R&D model faces liquidity challenges, with 80% of funding consumed during clinical stages, excluding ordinary investors [10][11] - Huajian Medical's strategy focuses on the medical innovation drug sector, aiming to create a "global free trading market" for innovative drug assets through its three-tiered structure [10][11] Group 4: Brand Transformation - Huajian Medical announced a brand upgrade alongside the fund's establishment, redefining its core brand "IVD" to emphasize Innovation, Verification, and Development [12][13] - The new logo symbolizes the company's vision of transforming from a medical device distributor to a builder of a decentralized scientific ecosystem [12][13] - The ultimate goal is to enable top-tier medical innovative drug IP to circulate freely like digital currency, creating a positive cycle among capital, R&D, and commercialization [12][13]

Core Viewpoint - 华检医疗 has signed a strategic cooperation framework agreement with 华大共赢 to establish the "华检华大共赢创新药知识产权代币化基金," aimed at investing in Web3 exchange ecosystem projects in Hong Kong and the US [1][6]. Group 1: Fund Establishment and Market Context - The newly established fund will be managed by 华大共赢, which will act as the general partner, while 华检医疗 will contribute as a limited partner [7]. - The fund's creation coincides with a significant recovery in the innovative drug capital market, with 18 companies in the healthcare sector successfully listing and raising over 18 billion yuan in the first half of the year [7]. - The innovative drug sector has become a hot investment area, with the 中证港股通创新药指数 increasing by over 124% since the beginning of the year [7]. Group 2: Web3 Strategy and Ecosystem - The fund represents a key component of 华检医疗's "NewCo+RWA+stablecoin" strategy, which aims to reshape the global medical innovation drug asset value chain [9]. - 华大共赢 will provide comprehensive services from due diligence to transaction design for selected innovative pharmaceutical companies or target assets [9]. - The ecosystem includes the "IVDNewCo Exchange" trading platform and the proprietary stablecoin IVD Dollar (IVDD), with regulatory applications already initiated in the US and Hong Kong [9][10]. Group 3: Market Potential and Value Chain Reconstruction - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP, with innovative drug asset tokenization having inherent advantages [11]. - The traditional pharmaceutical R&D model faces liquidity issues, with 80% of funding consumed during clinical phases, excluding ordinary investors [11]. - 华检医疗's approach focuses on the medical innovation drug sector, aiming to create a "global free trading market" through its three-tiered structure [11][12]. Group 4: Brand Transformation - 华检医疗 announced a brand upgrade alongside the fund's establishment, redefining its core brand "IVD" to emphasize Innovation, Verification, and Development [13][14]. - The new logo symbolizes the company's vision of enabling top medical innovation drug IP to circulate freely like digital currency [14][15].

Group 1 - The Hang Seng Index fell by 1.07%, down 270 points, closing at 24,906 points, while the Hang Seng Tech Index rose by 0.34% [1] - AI concept stocks showed strong performance, with multiple catalysts for AI applications in the second half of the year, indicating significant investment opportunities [1] - Notable gainers in AI stocks included Meitu Inc. (up 15.26%), Kingdee International (up 11.70%), and Kuaishou-W (up 8.98%) [1] Group 2 - Three-Six Pharmaceutical saw a rise of over 5% due to the overseas potential of SSGJ-707 being linked with Pfizer [2] - Huajian Medical surged over 10% after partnering with BGI to establish an innovative drug intellectual property tokenization fund [2] - Copper stocks declined across the board following Trump's announcement of a 50% tariff on imported semi-finished copper, with Zijin Mining falling by 4.93% [2]

Group 1 - Company shares of 华检医疗 (01931) have increased over 15%, with a cumulative rise of more than 120% in the month [1] - As of the report, the stock price is at 4.91 HKD, with a trading volume of 13.82 million HKD [1] - The company announced a strategic cooperation framework agreement with 华大共赢 to establish the IVD-BGI CoWin innovation drug intellectual property tokenization fund [1] Group 2 - The fund will invest in projects under the NewCo + RWA Web3 exchange ecosystem in Hong Kong, the US, or other overseas regions [1] - 华大共赢, initiated by the biotechnology leader 华大基因, has extensive investment experience and project resources in the innovative medical and pharmaceutical fields [1] - The company aims to address the pharmaceutical industry's pain points, where new drug development takes 10 years and 80% of funding is spent in clinical stages, by allowing ordinary investors access to high-value medical assets through RWA technology [1] Group 3 - The solution involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates [1] - The goal is to become the "Nasdaq + Uniswap" in the medical RWA field, ensuring compliance while achieving decentralized liquidity [1]

Group 1 - Company shares of 华检医疗 (01931) have increased over 15%, with a cumulative increase of over 120% in the month [1] - As of the report, the stock price is at 4.91 HKD, with a trading volume of 13.82 million HKD [1] - 华检医疗 has announced a strategic cooperation framework agreement with 华大共赢 to establish the IVD-BGI CoWin innovation drug intellectual property tokenization fund [1] Group 2 - The IVDNewCo Exchange is a Web3 trading ecosystem aimed at addressing pain points in the pharmaceutical industry, where new drug development takes 10 years and 80% of funding is spent in clinical stages [2] - The solution involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates using RWA technology [2] - The goal is to become the "Nasdaq + Uniswap" of the medical RWA field, ensuring compliance while achieving decentralized liquidity [2]

Group 1 - The company has entered into a strategic cooperation framework agreement with BGI CoWin to establish an innovative drug intellectual property tokenization fund [1] - The fund will invest in projects under the NewCo+RWA Web3 exchange ecosystem model in Hong Kong, the United States, or other overseas regions [1] - BGI CoWin will act as the general partner responsible for managing the NewCo innovative drug RWA fund, while the company will contribute as a limited partner [1] Group 2 - The strategic cooperation aims to enhance the company's business layout through a tripartite strategy of "NewCo+RWA+stablecoin" [2] - This collaboration is expected to strengthen the company's role in reshaping the global medical innovative drug asset value chain [2]